Back to top
more

Virtus LifeSci Biotech Clinical Trials ETF: (BBC)

(Delayed Data from NYSE) As of Dec 15, 2025 03:28 PM ET

$39.83 USD

39.825
13,278

-0.13 (-0.31%)

Volume: 13,278

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

After-Market: $39.80 -0.03 (-0.06 %) 4:38 PM ET

Zacks News

Sanghamitra Saha headshot

4 Worst ETF Areas of Q4

These ETF areas have been particularly painful in the bloodbath of the fourth quarter.

Sweta Killa headshot

Healthcare ETFs Sink on JNJ News, ACA Ruling: What???s Ahead?

Healthcare took a hit recently on Johnson & Johnson news and a federal judge ruling. The rough trading also spread into the ETF world.

Sweta Killa headshot

Top and Flop ETFs at Half-Way Q4

We have highlighted both the best and worst performing zones and their ETFs at halfway Q4.

Sanghamitra Saha headshot

ETF Areas That Spooked Investors in October

These ETF areas lost the most in the Halloween month and gave investors the chills.

Sanghamitra Saha headshot

Scared of a September Lull? Play 6 ETFs

These ETFs may perform well in ill-famed September due to solid fundamentals.

    Sanghamitra Saha headshot

    5 ETFs to Play in July

    Investors may tap these five ETFs for gains as President Trump aims the first shot in the trade war.

      Sweta Killa headshot

      5 Safe and Sound ETF Strategies for 2H

      After a bumpy ride in the first half of the year, global stocks are bouncing back despite the trade war fears.

        Sweta Killa headshot

        How to Build a Winning ETF Portfolio Amid Trade War Fears

        We have highlighted some strategies that could prove extremely beneficial for investors in a choppy market.

          Sweta Killa headshot

          Sarepta Pharma Pushes Two Biotech ETFs to New Highs

          The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

            Neena Mishra headshot

            Why These Small Cap Biotech ETFs are Soaring

            These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.

              Sweta Killa headshot

              Best and Worst ETFs of Last Week

              Several ETFs saw a huge decline while a few stood tall in the market turbulence.

                Sanghamitra Saha headshot

                4 Sector ETFs to Ride on Strong Beat Ratios

                Sector ETFs with strong beat ratios in fourth-quarter earnings.

                  Sweta Killa headshot

                  Biotech Crushing the Market: Best ETFs & Stocks YTD

                  The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.

                    Sweta Killa headshot

                    Biotech ETF (BBC) Hits New 52-Week High

                    This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

                      Sweta Killa headshot

                      M&A Waves Pushing Biotech ETFs Higher

                      The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.

                        Sanghamitra Saha headshot

                        Tax Reform: A Boon or Bane for Small-Cap ETFs?

                        Small-cap ETFs may be gaining on tax cut hopes but all is not rosy in the tax blueprint for the pint-sized stocks.

                          Sanghamitra Saha headshot

                          Value Biotech ETFs to Buy Now

                          A few reasons why you should buy value biotech ETFs for 2018

                            Sanghamitra Saha headshot

                            Top and Flop Sector ETFs of Q3

                            Inside the best and worst performing ETF areas of the third quarter.

                              Sweta Killa headshot

                              Best Sector ETF of Q3 and its Top-Performing Stocks

                              Inside the top performing stocks of top U.S.-focused ETF of Q3.

                                Sweta Killa headshot

                                Volatility Shakes Market: Top and Flop ETFs Over a Month

                                The long list of woes started with escalating tensions between the United States and North Korea from word of war.

                                  Sanghamitra Saha headshot

                                  Top and Flop ETFs of August: Metals Gain, Crops Crash

                                  Inside the best and worst performing ETF areas of the month of August.

                                    Sanghamitra Saha headshot

                                    Biotech ETFs Soar on Gilead-Kite Deal

                                    Gilead Sciences boosted the biotech ETF world on August 28 by announcing the buyout news of Kite Pharma.

                                      Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, PowerShares Dynamic Semiconductors Fund, PowerShares S&P SmallCap Utilities Portfolio, PowerShares S&P SmallCap Energy Fund and Guggenheim S&P SmallCap 600 Pure V

                                      The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, PowerShares Dynamic Semiconductors Fund, PowerShares S&P SmallCap Utilities Portfolio, PowerShares S&P SmallCap Energy Fund and Guggenheim S&P SmallCap 600 Pure Value

                                        Zacks Equity Research

                                        The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, Global X MSCI Argentina, iPath S&P 500 VIX Short-Term Futures, iPath Bloomberg Natural Gas Subindex Total Return and iPath Global Carbon

                                        The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials, Global X MSCI Argentina, iPath S&P 500 VIX Short-Term Futures, iPath Bloomberg Natural Gas Subindex Total Return and iPath Global Carbon

                                          Sweta Killa headshot

                                          Best and Worst Zones of Q1 and Their ETFs

                                          Most corners of ETF investing have performed exceptionally well in Q1 while a few areas are lagging.